IntegriCell® Cryopreservation Services from Cryoport Systems

IntegriCell cryopreservation services from Cryoport Systems are designed to advance cell therapy programs with precision and reliability. By delivering standardized, GMP-compliant solutions, IntegriCell ensures the highest quality leukapheresis-derived starting materials for cell-based therapies. Our facilities in Houston, Texas, and Villers-Les-Bouillet, Belgium utilize closed, automated systems to reduce contamination risks and human error. Each site has the capacity to process over 1,000 leukapheresis products annually, supporting scalability for growing therapeutic demands. Integrated with Cryoport Systems’ end-to-end temperature-controlled supply chain, IntegriCell also provides seamless transport and storage for critical materials. Rigorous quality control measures, including controlled monitored conditions and strict regulatory compliance, guarantee batch-to-batch consistency. This foundation of reliability helps researchers and manufacturers maintain confidence in every step of the process.

IntegriCell employs a validated Automated Closed Process (ACP) to cryopreserve leukapheresis material within an optimal 24-hour post-collection window, ensuring high cell recovery and viability rates of over 90%. Proprietary protocols minimize variability compared to manual methods, producing manufacture-ready leukopaks with consistent results. By extending the shelf life of these highly sensitive starting materials, IntegriCell decouples collection from drug production, enabling flexible manufacturing schedules and reducing costs. These standardized protocols support both autologous and allogeneic therapies, streamlining development from pre-clinical research through commercial stages. Strategic partnerships further enhance material availability by providing access to diverse donor pools. Through these capabilities, IntegriCell empowers organizations to accelerate life-saving therapies without compromising quality.